Evaluation of Serum Cytokines IL-12, 17and 22 Levels in Patients with Brain Tumors AL-Sherify Ahmed M.B.1, Darwesh Mayada Farhan1, Mezher Musa Nima1,* 1College of Science, University of Kufa, AL-Najaf, Iraq *Corresponding author: Musa Nima Mezher. E-mail: musan.alabbasi@uokufa.edu.iq
Online published on 30 April, 2019. Abstract Background There are over 120 brain tumor types and they were classified according to World Health Organization. Previously, attempts were made regarding chemosensitivity testing and molecular biomarkers methods were used as techniques during the management of different types of malignant tumors in routine clinical practice, especially in neuropathology. Current study was aimed to evaluate some immune-markers in Iraqi patients by (ELISA) to assess the different levels of IL-12, IL-17 and IL-22 to illustrate ability of tumor in immune-modulatory activity to increase the progression of disease. Also, it was hoped that these markers can be used as indicators for rapid identification of novel brain tumor in patients, directly from their sera samples in vitro as chemo-sensitivity assay. Methodology Current study involved 68 Iraqi brain tumor patients (30 Glioma; 14Glioblastoma Multi form (GBM), 10 Astrocytomas, 4 Ependymomas and 2 Oligodendrogliomas) 24 Meningiomas, 5 Schwannoma and other 8 different tumor types were investigated for serum level of IL-12, IL-17 and IL-22 by (ELISA) assay. Control samples were also enrolled in the study, including 30 healthy subjects (18 males and 12 females). Results The present study illustrated that IL-12 mean serum level decreased to (33.9±9.9pg/ml) compared with its level in controls (47.68±3.5pg/ml). Also, there wasa higher reduction in its level in Gliomas, Meningioma and Schwannoma (30.55±10.8, 37.6±8.4 and 33.8±8.7pg/ml, respectively). IL-17 serum level was highly significantly increased with a mean level (42.3±9.7pg/ml) as compared with control level (10.46±3.5pg/ml). In Gliomas, its serum level was (67.8±11.8 pg/ml) compared with its level in Meningioma and Schwannoma (33.8±3.4and 27±7.7pg/ml, respectively). IL-22 showed significant increase (67±20pg/ml) in comparison with control level (22±5pg/ml). In Gliomas its level was (93±3pg/ml) compared with its level in Meningioma, chwannoma (60±2.6 and 77.78±7.4pg/ml, respectively). Conclusions This study showed that all brain tumor types patients had increased circulating serum levels of IL-17 and IL-22, while decreased of IL-12. These data indicated that brain tumors might have a systemic effect on the immune system. The data also suggested a possible role of some Interleukins in pathogenesis of brain tumor. IL-12, IL-17 and IL-22 may also be a potential biomarkers and/or immunotherapeutic targets in some brain tumor types. Top Keywords Brain tumor, Cytokines, IL-12, IL-17, IL-22, Biomarker, Gliomas. Top |